Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOVIE INC.BIVI · Entity 7702 | Director | November 20, 2024 | January 07, 2025 |
| Celularity IncCELU · Entity 7145 | Director · Chief Executive Officer | April 13, 2026 | April 15, 2026 |
| Cryoport, Inc.CYRX · Entity 5125 | Director | June 05, 2026 | June 09, 2026 |
| MedAvail Holdings, Inc.MYOS · Entity 94590 | Director | March 31, 2020 | April 06, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOVIE INC.
Report date November 20, 2024 · Filed January 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.36 · Expires 2029-11-20 | Direct | 49,800 |
Reported balance
After 2024-11-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-11-20 · Grant · Acquired 49,800 · Balance 49,800 F1: The options vest in four equal installments on February 8, 2025, May 8, 2025, August 8, 2025 and the earlier of November 8, 2025 and the date of the issuer's 2025 annual shareholders' meeting. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.90 · Expires 2029-12-20 | Direct | 21,815 |
Reported balance
After 2024-12-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-12-20 · Grant · Acquired 21,815 · Balance 21,815 F2: The options vest in three equal installments on December 20, 2024, December 20, 2025 and December 20, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest in four equal installments on February 8, 2025, May 8, 2025, August 8, 2025 and the earlier of November 8, 2025 and the date of the issuer's 2025 annual shareholders' meeting.
F2: The options vest in three equal installments on December 20, 2024, December 20, 2025 and December 20, 2026.
Celularity Inc
Report date April 13, 2026 · Filed April 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 2,853,553 |
Ending reported balance
After 2026-04-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-04-13 · Exercise / conversion · Acquired 3,281 · Balance 2,854,735 F1: Represents the conversion upon vesting of restricted stock units (RSUs) into Class A Common Stock. On April 13, 2022, the reporting person was granted 13,123 RSUs, 25% of which vested on April 13, 2026. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on April 28, 2022. Row 2 · 2026-04-13 · Tax withholding · Disposed 1,182 · Balance 2,853,553 F2: This line reflects the tax withholding on the vesting of RSUs that vested on April 13, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-13 · Exercise / conversion · Disposed 3,281 · Balance 0 F3: Each restricted stock unit is the economic equivalent of one share of Celularity Inc. Class A Common Stock. F4: On April 13, 2022, the reporting person was granted 13,123 RSUs, 25% of which vested on April 13, 2026. The Class A Common Stock into which such vested RSUs converted on April 13, 2026 is reported in Table I on this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the conversion upon vesting of restricted stock units (RSUs) into Class A Common Stock. On April 13, 2022, the reporting person was granted 13,123 RSUs, 25% of which vested on April 13, 2026. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on April 28, 2022.
F2: This line reflects the tax withholding on the vesting of RSUs that vested on April 13, 2026.
F3: Each restricted stock unit is the economic equivalent of one share of Celularity Inc. Class A Common Stock.
F4: On April 13, 2022, the reporting person was granted 13,123 RSUs, 25% of which vested on April 13, 2026. The Class A Common Stock into which such vested RSUs converted on April 13, 2026 is reported in Table I on this Form 4.
Cryoport, Inc.
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 61,625 |
Reported balance
After 2026-06-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 10,350 · Balance 61,625 F1: Reflects grant of restricted stock rights that vest in full on June 5, 2027, and upon vesting automatically convert to shares of common stock on a one-for-one basis. |
| Option (Right to Buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $15.70 · Expires 2033-06-05 | Direct | 16,077 |
Reported balance
After 2026-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-05 · Grant · Acquired 16,077 · Balance 16,077 F2: 1/12th of the options vest on the 5th of the month for twelve months beginning July 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects grant of restricted stock rights that vest in full on June 5, 2027, and upon vesting automatically convert to shares of common stock on a one-for-one basis.
F2: 1/12th of the options vest on the 5th of the month for twelve months beginning July 5, 2026.
MedAvail Holdings, Inc.
Report date March 31, 2020 · Filed April 06, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 119,364 |
Reported balance
After 2020-03-31 transaction · row 1
1 source rowRow 1 · 2020-03-31 · Grant · Acquired 3,306 · Balance 119,364 F1: The shares of common stock were awarded to the reporting person under the registrant's 2012 Equity Incentive Plan and will vest immediately. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock were awarded to the reporting person under the registrant's 2012 Equity Incentive Plan and will vest immediately.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 29, 2022 Filed May 4, 2022 00:01 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantCommon Stock | 7,203 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-055438 · tm2214402-3_4seq1.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,203 F1 · security: Reflects grant of restricted stock rights that vest in full on April 29, 2023, and upon vesting automatically convert to shares of common stock on a one-for-one basis. F1 · price: Reflects grant of restricted stock rights that vest in full on April 29, 2023, and upon vesting automatically convert to shares of common stock on a one-for-one basis. Read SEC document |
| April 13, 2022 Filed Apr 29, 2022 01:05 UTC | Celularity Inc CELU · Entity 7145 | GrantStock Option (Right to Buy) · Derivative | 384,801 | $0.00 Strike: $10.16 | $0.00 |
DisclosureSEC source: 0000899243-22-015912 · doc4.xml · derivative · entry 2 Hariri Robert J · CIK 0001398815 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,801 Underlying: Class A Common Stock · 384,801 shares Expires 2032-04-13 F2 · derivative.exercise_date: This option shall vest and become exercisable over a four-year period, with 25% of the option vesting on the one-year anniversary of the grant date, and the remainder vesting in equal monthly installments thereafter so that vested in full on the four-year anniversary of the grant date, and subject to the Reporting Person's continuous service on each vesting date. Read SEC document |
| April 13, 2022 Filed Apr 29, 2022 01:05 UTC | Celularity Inc CELU · Entity 7145 | GrantClass A Common Stock | 131,234 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-015912 · doc4.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,865,923 F1 · price: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A Common Stock. The RSUs is subject to time-based vesting over a four-year period, with 25% vesting on the one-year anniversary of the grant date, and the remainder vesting in equal annual installments thereafter so that vested in full on the four-year anniversary of the grant date, and subject to the Reporting Person's continuous service on each vesting date. Read SEC document |
| April 05, 2022 Filed Apr 20, 2022 20:46 UTC | BIOVIE INC. BIVI · Entity 7702 | GrantStock Option (right to buy) · Derivative | 122,250 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001062993-22-010536 · form4.xml · derivative · entry 1 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,250 Underlying: Common Stock · 122,250 shares Expires 2032-04-05 F1 · security: Options granted pursuant to the Company???s 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options were 25% vested upon grant, with the remaining 75% vesting ratably over a three-year period on each anniversary of the grant date. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 22:15 UTC | Celularity Inc CELU · Entity 7145 | GrantStock Option (Right to Buy) · Derivative | 2,690,079 | $0.00 Strike: $10.23 | $0.00 |
DisclosureSEC source: 0001213900-21-047756 · ownership.xml · derivative · entry 1 Hariri Robert J · CIK 0001398815 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,690,079 Underlying: Class A Common Stock · 2,690,079 shares Expires 2031-09-09 F1 · derivative.exercise_date: This option shall vest and become exercisable as follows: 50% is fully-vested as of the grant date; 50% is subject to time-based vesting over a four-year period from the July 16, 2021 closing of the business combination, with 25% of this tranche vesting on the one-year anniversary of the closing (July 16, 2022), and the remainder vesting monthly thereafter so that vested in full on the four-year anniversary of the business combination closing date, and subject to the Reporting Person's continuous service on each vesting date. Read SEC document |
| July 16, 2021 Filed Jul 21, 2021 01:11 UTC | Celularity Inc CELU · Entity 7145 | GrantStock Option (Right to Buy) · Derivative | 1,921,485 | $0.00 Strike: $10.21 | $0.00 |
DisclosureSEC source: 0001209191-21-047510 · doc4.xml · derivative · entry 5 Hariri Robert J · CIK 0001398815 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,921,485 Underlying: Class A Common Stock · 1,921,485 shares Expires 2031-07-16 F3 · price: Pursuant to the Business Combination Agreement, each security to purchase shares of Legacy Celularity common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a 1-to-0.768594024295126 conversion ratio. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| July 16, 2021 Filed Jul 21, 2021 01:11 UTC | Celularity Inc CELU · Entity 7145 | GrantStock Option (Right to Buy) · Derivative | 384,297 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0001209191-21-047510 · doc4.xml · derivative · entry 4 Hariri Robert J · CIK 0001398815 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,297 Underlying: Class A Common Stock · 384,297 shares Expires 2031-07-16 F3 · price: Pursuant to the Business Combination Agreement, each security to purchase shares of Legacy Celularity common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a 1-to-0.768594024295126 conversion ratio. F5 · derivative.exercise_date: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, December 15, 2019, with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date. Read SEC document |
| July 16, 2021 Filed Jul 21, 2021 01:11 UTC | Celularity Inc CELU · Entity 7145 | GrantStock Option (Right to Buy) · Derivative | 174,680 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0001209191-21-047510 · doc4.xml · derivative · entry 3 Hariri Robert J · CIK 0001398815 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,680 Underlying: Class A Common Stock · 174,680 shares Expires 2031-07-16 F3 · price: Pursuant to the Business Combination Agreement, each security to purchase shares of Legacy Celularity common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a 1-to-0.768594024295126 conversion ratio. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| July 16, 2021 Filed Jul 21, 2021 01:11 UTC | Celularity Inc CELU · Entity 7145 | GrantStock Option (Right to Buy) · Derivative | 349,360 | $0.00 Strike: $2.87 | $0.00 |
DisclosureSEC source: 0001209191-21-047510 · doc4.xml · derivative · entry 2 Hariri Robert J · CIK 0001398815 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,360 Underlying: Class A Common Stock · 349,360 shares Expires 2031-07-16 F3 · price: Pursuant to the Business Combination Agreement, each security to purchase shares of Legacy Celularity common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a 1-to-0.768594024295126 conversion ratio. F2 · derivative.exercise_date: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, February 28, 2018, with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date. Read SEC document |
| July 16, 2021 Filed Jul 21, 2021 01:11 UTC | Celularity Inc CELU · Entity 7145 | OtherClass A Common Stock | 7,734,689 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-047510 · doc4.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,734,689 F1 · price: Pursuant to the Merger Agreement and Plan of Merger and Reorganization, dated January 8, 2021 (the "Business Combination Agreement"), by and among GX Acquisition Corp. ("GX"), Alpha First Merger Sub Corp., Celularity LLC and Celularity Inc. ("Legacy Celularity"), each share of Legacy Celularity common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into the right to receive a number of shares of the Issuer's common stock based on a 1-to-0.768594024295126 conversion ratio. Upon consummation of the business combination, GX changed its name to "Celularity Inc." Read SEC document |
| April 30, 2021 Filed May 7, 2021 22:42 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantRestricted Stock Rights · Derivative | 2,708 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-063251 · tm2115610d4_4.xml · derivative · entry 2 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,708 Underlying: Common Stock · 2,708 shares Expires 2022-04-30 F2 · derivative.exercise_price: Each restricted stock right represents a contingent right to receive one share of CYRX common stock. Read SEC document |
| April 30, 2021 Filed May 7, 2021 22:42 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOption to purchase common stock · Derivative | 5,416 | $0.00 Strike: $56.57 | $0.00 |
DisclosureSEC source: 0001104659-21-063251 · tm2115610d4_4.xml · derivative · entry 1 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,416 Underlying: Common Stock · 5,416 shares Expires 2028-04-30 F1 · derivative.exercise_date: 1/12th of options vest on the 30th of the month for twelve months beginning May 30, 2021. Read SEC document |
| December 18, 2020 Filed Sep 28, 2021 20:25 UTC | BIOVIE INC. BIVI · Entity 7702 | GrantStock Option (right to buy) · Derivative | 95,900 | $0.00 Strike: $13.91 | $0.00 |
DisclosureSEC source: 0001520138-21-000583 · ownership.xml · derivative · entry 1 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,900 Underlying: Common Stock · 95,900 shares Expires 2025-12-18 F1 · derivative.exercise_date: This option was 25% vested upon grant, with an additional 25% on each of the first three anniversaries of the grant. Read SEC document |
| July 20, 2020 Filed Jul 31, 2020 21:20 UTC | Cryoport, Inc. CYRX · Entity 5125 | OtherWarrants to purchase common stock · Derivative | 15,300 | $0.00 Strike: $3.57 | $0.00 |
DisclosureSEC source: 0001104659-20-089168 · tm2026274d2_4.xml · derivative · entry 2 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,300 shares Expires 2020-07-29 Read SEC document |
| July 20, 2020 Filed Jul 31, 2020 21:20 UTC | Cryoport, Inc. CYRX · Entity 5125 | OtherCommon Stock | 15,300 | $3.57 | $54,621.00 |
DisclosureSEC source: 0001104659-20-089168 · tm2026274d2_4.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,600 Read SEC document |
| May 01, 2020 Filed May 6, 2020 01:12 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOptions to purchase common stock · Derivative | 35,000 | $0.00 Strike: $18.02 | $0.00 |
DisclosureSEC source: 0001104659-20-057100 · tm2018763d5_4.xml · derivative · entry 1 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-05-01 F1 · derivative.exercise_date: 1/12 of these options vest and become exercisable on the 1st of each month for twelve (12) months beginning on 06/01/2020. Read SEC document |
| March 31, 2020 Filed Apr 6, 2020 21:13 UTC | MedAvail Holdings, Inc. MYOS · Entity 94590 | GrantCommon Stock | 3,306 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-20-008713 · ownership.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,364 F1 · price: The shares of common stock were awarded to the reporting person under the registrant's 2012 Equity Incentive Plan and will vest immediately. Read SEC document |
| May 02, 2019 Filed May 3, 2019 23:53 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOptions to purchase common stock · Derivative | 35,000 | $0.00 Strike: $14.35 | $0.00 |
DisclosureSEC source: 0001144204-19-023717 · tv520658_4.xml · derivative · entry 1 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-05-02 F1 · derivative.exercise_date: 1/12 of these options vested and became exercisable in equal monthly installments on the 2nd of each month r the next twelve (12) months beginning on 05/02/2019. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 17:09 UTC | MedAvail Holdings, Inc. MYOS · Entity 94590 | GrantCommon Stock | 10,955 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-19-001970 · ownership.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,058 F1 · price: The shares of common stock were awarded to the reporting person under the registrant's 2012 Equity Incentive Plan and will vest immediately. Read SEC document |
| May 17, 2018 Filed May 22, 2018 01:01 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOptions to purchase common stock · Derivative | 35,000 | $0.00 Strike: $9.29 | $0.00 |
DisclosureSEC source: 0001144204-18-030145 · tv494662_4.xml · derivative · entry 2 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2028-05-17 F2 · derivative.exercise_date: 1/12 of these options vest and become exercisable in equal monthly installments on the 17th of each month for the next twelve (12) months beginning on 06/17/2018. Options issued under the compensation plan for non-employee directors for services as director during the 2018/19 term. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 16:05 UTC | MedAvail Holdings, Inc. MYOS · Entity 94590 | GrantCommon Stock | 7,353 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-18-000171 · f4010318hariri_myos.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,103 F1 · price: The shares of common stock were awarded to the reporting person under the registrant's 2012 Equity Incentive Plan and will vest immediately. Read SEC document |
| June 23, 2017 Filed May 22, 2018 01:01 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOptions to purchase common stock · Derivative | 35,000 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001144204-18-030145 · tv494662_4.xml · derivative · entry 1 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2027-06-23 F1 · derivative.exercise_date: 1/12 of these options vested and became exercisable in equal monthly installments on the 23rd of each month for the next twelve (12) months beginning on 07/23/2017. Options issued under the compensation plan for non-employee directors for services as director during the 2017/18 term. Read SEC document |
| December 28, 2016 Filed Dec 30, 2016 16:32 UTC | MedAvail Holdings, Inc. MYOS · Entity 94590 | GrantCommon Stock | 4,386 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-16-019817 · f4122816hariri_myosrens.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,750 F1 · price: The shares of common stock were awarded to the reporting person under the registrant's 2012 Equity Incentive Plan and will vest on January 1, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.